In vitro interactions among echinocandins against Aspergillus fumigatus: lack of concordance among methods.

Drug combinations are increasingly being explored as a means of improving outcomes in cases of invasive aspergillosis. However, the optimal methods for assessing in vitro drug combinations are unclear. We investigated whether echinocandin drug combinations have potentially useful interactions against Aspergillus fumigatus. We explored the in vitro interactions of three echinocandins (caspofungin [CSP], anidulafingin [ANF], and micafungin [MCF]) by three methods, i.e., (i) checkerboard assay, (ii) disk diffusion assay, and (iii) E-test/agar dilution. The checkerboard experiments revealed different interactions between echinocandin pairs depending on the drug combination tested. Specifically, the combination of CSF and either ANF or MCF yielded a fractional inhibitory concentration (FIC) index range of 0.15-2.0. Whereas the combination of MCF and ANF yielded an FIC index range of 0.19-0.31, consistent with synergistic interaction. In contrast, all echinocandin pairs appeared indifferent by the disk diffusion method. Moreover, the combination of MCF and ANF appeared antagonistic when the two drugs were tested using the E-test/agar dilution method with both the FKS1 wild-type and echinocandin-resistant fks1 mutant strains. Our results highlight methodological problems inherent in in vitro antifungal combination testing. We did not find compelling evidence of inter-echinocandin synergy that could serve as a basis for further in vivo experimentation.

[1]  B. Alexander,et al.  Fungal infections in transplant and oncology patients. , 2010, Infectious disease clinics of North America.

[2]  G. Klintmalm,et al.  Combination of Voriconazole and Caspofungin as Primary Therapy for Invasive Aspergillosis in Solid Organ Transplant Recipients: A Prospective, Multicenter, Observational Study , 2006, Transplantation.

[3]  Russell E. Lewis,et al.  Toward more effective antifungal therapy: the prospects of combination therapy , 2004, British journal of haematology.

[4]  N. Wiederhold,et al.  The echinocandin antifungals: an overview of the pharmacology, spectrum and clinical efficacy , 2003, Expert opinion on investigational drugs.

[5]  F. Odds,et al.  Synergy, antagonism, and what the chequerboard puts between them. , 2003, The Journal of antimicrobial chemotherapy.

[6]  J. Rex,et al.  Comparative Evaluation of Disk Diffusion with Microdilution Assay in Susceptibility Testing of Caspofungin against Aspergillus and Fusarium Isolates , 2002, Antimicrobial Agents and Chemotherapy.

[7]  M. Klepser,et al.  Comparison of Etest, chequerboard dilution and time-kill studies for the detection of synergy or antagonism between antifungal agents tested against Candida species. , 2002, The Journal of antimicrobial chemotherapy.

[8]  P. J. Donnelly,et al.  Comparison of Spectrophotometric and Visual Readings of NCCLS Method and Evaluation of a Colorimetric Method Based on Reduction of a Soluble Tetrazolium Salt, 2,3-Bis {2-Methoxy-4-Nitro-5-[(Sulfenylamino) Carbonyl]-2H- Tetrazolium-Hydroxide}, for Antifungal Susceptibility Testing of AspergillusSpeci , 2001, Journal of Clinical Microbiology.

[9]  D. Kontoyiannis,et al.  Itraconazole-Amphotericin B Antagonism inAspergillus fumigatus: an E-Test-Based Strategy , 2000, Antimicrobial Agents and Chemotherapy.

[10]  L. Reimer,et al.  Antibiotics in laboratory medicine , 1987 .

[11]  J. Ruiloba [Antimicrobial combinations]. , 1972, Gaceta medica de Mexico.